Sage Journals: Discover world-class research

Abstract

Background

Updated estimates of the productivity losses per HIV infection due to premature HIV mortality are needed to help quantify the economic burden of HIV and inform cost-effectiveness analyses.

Methods

We used the human capital approach to estimate the productivity loss due to HIV mortality per HIV infection in the United States, discounted to the time of HIV infection. We incorporated published data on age-specific annual productivity, life expectancy at HIV diagnosis, life-years lost from premature death among persons with HIV (PWH), the number of years from HIV infection to diagnosis, and the percentage of deaths in PWH attributable to HIV. For the base case, we used 2018 life expectancy data for all PWH in the United States. We also examined scenarios using life expectancy in 2010 and life expectancy for cohorts on antiretroviral therapy (ART). We conducted sensitivity analyses to understand the impact of key input parameters.

Results

We estimated the base-case overall average productivity loss due to HIV mortality per HIV infection at $65,300 in 2022 US dollars. The base-case results showed a 45% decrease in the estimated productivity loss compared with the results when applying life expectancy data from 2010. Productivity loss was 83% lower for cohorts of PWH on ART compared with the base-case scenario. Results were sensitive to assumptions about percentage of deaths attributable to HIV and heterogeneity in age at death.

Conclusion

This study provides valuable insights into the economic impact of HIV mortality, illustrating reductions in productivity losses over time due to advancements in treatments.

Highlights

Updated estimates of productivity losses per HIV infection due to premature HIV mortality can help assess the total economic burden of HIV in the United States.

This study estimates productivity losses per HIV infection for overall, by sex, and by varying ages of HIV infection.

Advancement in treatment has contributed to a significant reduction in productivity losses due to premature HIV mortality in the United States over the past decade.

Keywords

ART HIV premature HIV mortality productivity loss

Get full access to this article

View all access options for this article.

References

Finkelstein

Corso

Cost-of-illness analyses for policy making: a cautionary tale of use and misuse. Expert Rev Pharmacoecon Outcomes Res. 2003;3(4):367–9. DOI: 10.1586/14737167.3.4.367

Krol

Brouwer

Rutten

Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31(7):537–49. DOI: 10.1007/s40273-013-0056-3

Rice

DP.

Estimating the cost of illness. Am J Public Health Nations Health. 1967;57(3):424–40. DOI: 10.2105/ajph.57.3.424

Weintraub

WS.

The economic burden of illness. JAMA Netw Open. 2023;6(3):e232663. DOI: 10.1001/jamanetworkopen.2023.2663

Wang

Grosse

Schooley

MW.

Conducting research on the economics of hypertension to improve cardiovascular health. Am J Prev Med. 2017;53(6 suppl 2):S115–7. DOI: 10.1016/j.amepre.2017.08.005

Benjamin

Blaha

Chiuve

, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. DOI: 10.1161/CIR.0000000000000485

Leigh

JP.

Economic burden of occupational injury and illness in the United States. Milbank Q. 2011;89(4):728–72. DOI: 10.1111/j.1468-0009.2011.00648.x

Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2018–2022. Available from: https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html.

Farnham

Gopalappa

Sansom

, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–9. DOI: 10.1097/QAI.0b013e3182973966

10.

Bingham

Shrestha

Khurana

Jacobson

Farnham

PG.

Estimated lifetime HIV-related medical costs in the United States. Sex Transm Dis. 2021;48(4):299–304. DOI: 10.1097/OLQ.0000000000001366

11.

Schackman

Fleishman

, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015;53(4):293–301. DOI: 10.1097/MLR.0000000000000308

12.

Farnham

Holtgrave

Gopalappa

Hutchinson

Sansom

SL.

Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8. DOI: 10.1097/QAI.0b013e3182a5c8d4

13.

Cohen

Beaubrun

Ding

Wade

Hines

DM.

Estimation of the incremental cumulative cost of HIV compared with a non-HIV population. Pharmacoecon Open. 2020;4(4):687–96. DOI: 10.1007/s41669-020-00209-8

14.

Hutchinson

Farnham

Dean

, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43(4):451–7. DOI: 10.1097/01.qai.0000243090.32866.4e

15.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. [Accessed 19 February, 2024].

16.

Fischl

Richman

Grieco

, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–91. DOI: 10.1056/NEJM198707233170401

17.

Thoueille

Choong

Cavassini

Buclin

Decosterd

LA.

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290–302. DOI: 10.1093/jac/dkab324

18.

Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022: HIV Surveillance Supplemental Report 2024. 2024. Available from: https://stacks.cdc.gov/view/cdc/156511. [Accessed 11 November, 2024].

19.

Weisbrod

BA.

The valuation of human capital. J Political Econ. 1961;69(5):425–36.

20.

Hanly

Ahern

Sharp

Ursul

Loughnane

The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study. Eur J Health Econ. 2022;23(2):249–59. DOI: 10.1007/s10198-021-01351-8

21.

Hanly

Sharp

The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer. 2014;14:224. DOI: 10.1186/1471-2407-14-224

22.

Darba

Marsa

The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period. BMC Cancer. 2019;19(1):992. DOI: 10.1186/s12885-019-6243-7

23.

Mosegui

GBG

Antonanzas

de Mello Vianna

. Cost of lost productivity from acute respiratory infections in South America. Rev Panam Salud Publica. 2023;47:e65. DOI: 10.26633/RPSP.2023.65

24.

Ortega-Ortega

Hanly

Pearce

Soerjomataram

Sharp

Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018. Int J Cancer. 2022;150(4):580–93. DOI: 10.1002/ijc.33826

25.

Menzin

Marton

Menzin

Willke

Woodward

Federico

Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation. BMC Med Res Methodol. 2012;12:87. DOI: 10.1186/1471-2288-12-87

26.

Marcus

Leyden

Alexeeff

, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000–2016. JAMA Netw Open. 2020;3(6):e207954. DOI: 10.1001/jamanetworkopen.2020.7954

27.

Bosh

Johnson

Hernandez

, et al. Vital signs: deaths among persons with diagnosed HIV infection, United States, 2010–2018. MMWR Morb Mortal Wkly Rep. 2020;69(46):1717–24.

28.

Crepaz

Song

Lyss

Hall

HI.

Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014–2018. AIDS. 2021;35(13):2181–90. DOI: 10.1097/QAD.0000000000003008

29.

Sanders

Neumann

Basu

, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103. DOI: 10.1001/jama.2016.12195

30.

Siddiqi

Johnson

Hernandez

Song

Life expectancy after HIV diagnosis 2008–2018, United States [Abstract 761]. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 12–16, 2022 [virtual]. Available from: https://www.croiconference.org/abstract/life-expectancy-after-hiv-diagnosis-2008-2018-united-states/.

31.

Siddiqi

Hall

Song

Population-based estimates of life expectancy after HIV diagnosis: United States 2008–2011. J Acquir Immune Defic Syndr. 2016;72(2):230–6. DOI: 10.1097/QAI.0000000000000960

32.

Trickey

Sabin

Burkholder

, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295–307. DOI: 10.1016/S2352-3018(23)00028-0

33.

Arias

United States life tables, 2019. Natl Vital Stat Rep. 2022;70(19):1–59.

34.

Arias

Heron

United States life tables, 2014. Natl Vital Stat Rep. 2017;66(4):1–64.

35.

Grosse

Krueger

Pike

Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22(6):501–8. DOI: 10.1080/13696998.2018.1542520

36.

US Bureau of Labor Statistics. Consumer price index. 2023. Available from: https://www.bls.gov/cpi/. [Accessed 7 November, 2023].

37.

Centers for Disease Control and Prevention. HIV surveillance report, 2021. Available from: https://stacks.cdc.gov/view/cdc/149071.

38.

Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96. DOI: 10.1086/652283

39.

Centers for Disease Control and Prevention. Underlying cause of death, 2018–2021, Single race results. CDC WONDER. Available from: https://wonder.cdc.gov/. [Accessed 22 January, 2024].

40.

HIV.gov. U.S. statistics. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics/. [Accessed 22 January, 2024].

41.

Peruski

Linley

Delaney

DiNenno

Johnson

AS.

Time from HIV infection to diagnosis in the U.S., 2014–2018. Am J Prev Med. 2021;61(5):636–43. DOI: 10.1016/j.amepre.2021.04.015

42.

Edwards

Cole

Breger

, et al. Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population. Clin Infect Dis. 2022;75(5):867–74. DOI: 10.1093/cid/ciab1030

43.

Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. Vol. 25. No. 2: HIV surveillance supplemental report 2018. 2020. Available from: https://stacks.cdc.gov/view/cdc/149255. [Accessed 1 August, 2025].

44.

Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas-2011. Vol. 18. No. 5. HIV surveillance supplemental report 2013. 2013. Available from: https://stacks.cdc.gov/view/cdc/149199. [Accessed 15 August, 2025].

45.

Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2017–2021. HIV surveillance supplemental report, 2023 28 (No 3). 2023. Available from: https://stacks.cdc.gov/view/cdc/149080. [Accessed 29 November, 2023].

46.

Maulsby

Ratnayake

Hesson

Mugavero

Latkin

CA.

A scoping review of employment and HIV. AIDS Behav. 2020;24(10):2942–55. DOI: 10.1007/s10461-020-02845-x

47.

Rueda

Raboud

Plankey

, et al. Labor force participation and health-related quality of life in HIV-positive men who have sex with men: the Multicenter AIDS Cohort Study. AIDS Behav. 2012;16(8):2350–60. DOI: 10.1007/s10461-012-0257-3

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Estimating Productivity Losses per HIV Infection due to Premature HIV Mortality in the United States

Abstract

Background

Methods

Results

Conclusion

Highlights

Keywords

Get full access to this article

References

Supplementary Material